Valuation

CGENCompugen

StockNasdaqIsraelHealth careEU retail investors: available

+9.2% today · +32.1% over a year

8/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 86% of the instruments we score

Quality: among the best of its peers; priced lower than most peers. No dividend.

Compugen (CGEN) valuation against sector peers: P/E 5.7 (sector median 25.8), P/B 2.0, EV/EBIT 3.3, free-cash-flow yield 15.5%, P/S 2.8.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricCGENSector medianvs median
P/E5.725.8 · n=2678% below
P/B2.03.6 · n=4545% below
P/S2.84.7 · n=4041% below
EV/EBIT3.322.8 · n=2886% below
Free-cash-flow yield15.5%3.8% · n=39312% above
Dividend yield0.00%0.19% · n=99100% below
Return on equity44.8%5.2% · n=56761% above
Return on invested capital128.1%6.5% · n=471,879% above
Gross margin87.3%70.2% · n=3924% above
Net debt / EBITDA−3.142.08 · n=25251% below

Value factor: 89 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NVSNovartis AG22.36.818.75.6%2.4%10/10
NOVNNovartis AG22.26.718.65.7%2.8%10/10
AZNAstraZeneca PLC28.76.023.14.0%1.1%5/10
AZNAstraZeneca plc28.66.023.04.0%1.7%6/10
NVONovo Nordisk A/S12.06.310.44.8%4.5%8/10
SNYSanofi13.41.518.26.9%4.4%7/10
SANSanofi SA13.41.518.26.9%4.8%9/10
GSKGSK plc14.45.011.77.8%3.6%9/10
TEVATeva Pharmaceutical Industries Limited99.16.343.82.5%0.0%6/10
ALCAlcon37.41.729.24.7%0.4%4/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 Dec 2025 · filed 02 Mar 2026